1-2 of 2
Wahid Hanna
Close
Sort by
Journal Articles

Risk-Adapted Therapy in Adults with Burkitt Lymphoma: Results of NCI 9177, a Multicenter Prospective Phase II Study of DA-EPOCH-R

Mark Roschewski, MD, Kieron Dunleavy, MD, Jeremy S. Abramson, MD MMSc, Brian K Link, MD, Samir Parekh, MD, Deepa Jagadeesh, MDMPH, Philip Bierman, MD, Ronald T. Mitsuyasu, MD, Ramakrishna Battini, MD, Peter R. Watson, MD, David Peace, MD, Wahid Hanna, MD, Bayard L. Powell, MD, Timothy E. O'Brien, MD, David King, MD, Christopher Melani, MD, Andrea Lucas, RN, Seth M. Steinberg, PhD, Brad S Kahl, MD, Jonathan W. Friedberg, MD, Richard F. Little, MDMPH, Nancy L. Bartlett, MD, Michelle A. Fanale, MD, Ariela Noy, MD, Wyndham H. Wilson, MD PhD
Journal: Blood
Blood (2017) 130 (Supplement 1): 188.
https://doi.org/10.1182/blood.V130.Suppl_1.188.188
Published: 2017
Journal Articles

Treatment of von Willebrand disease with a high-purity factor VIII/von Willebrand factor concentrate: a prospective, multicenter study: Presented in part at the meeting of the International Society of Thrombosis and Haemostasis in Washington, DC, August 1999.

Clinical Trials & Observations
Pier M. Mannucci, Juan Chediak, Wahid Hanna, John Byrnes, Marlies Ledford, Bruce M. Ewenstein, Anastassios D. Retzios, Barbara A. Kapelan, Richard S. Schwartz, Craig Kessler, the Alphanate Study Group
Journal: Blood
Blood (2002) 99 (2): 450–456.
https://doi.org/10.1182/blood.V99.2.450
Published: 2002